Companies › Buzzard Pharmaceuticals
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| isunakinra IL-1 receptor 1 inhibitor | IL1R1 | Phase 2 | Colorectal Cancer Metastatic; Triple-Negative Breast Cancer (TNBC) | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06634875 | isunakinra | Phase 2 | Colorectal Cancer Metastatic | Oncology | Jun 2027 |
| NCT07698106 | isunakinra | Phase 1 | Triple-Negative Breast Cancer (TNBC) | Oncology | Aug 2034 |
Cellvax Therapeutics Spectrum Pharmaceuticals Newish Technology (Beijing) BrainChild Bio TVAX Biomedical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.